ZUG, Switzerland and BOSTON, Oct. 01, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...
Gene editing is growing up. Ten years after Science magazine named CRISPR its 2015 “Breakthrough of the Year,” this revolutionary gene editing technology has become a workhorse of modern biology. In ...
CRISPR Therapeutics recently presented new preclinical data at the ESGCT 2025 Annual Congress showing its investigational CTX460, using the SyNTase gene editing platform, achieved greater than 90% ...
Traditional breeding and genetic modification methods have struggled to keep pace with the rapid evolution of plant viruses. CRISPR/Cas systems, originally derived from bacterial immune responses, ...
CRISPR Therapeutics AG (NASDAQ:CRSP) reported new topline study results on Wednesday to establish risk factors for atherosclerotic heart disease. The company disclosed data regarding the first 10 ...
-New Phase 1 clinical data for CTX310™ continues to demonstrate dose-dependent reductions in triglycerides (TG) and low-density lipoprotein (LDL), with peak reduction of up to 82% in TG and up to 86% ...
Two days after Intellia voluntarily paused dosing due to safety concerns, the regulator stepped in with an official hold that ...
A new study has revealed that the gene HMGN1 is a key driver of congenital heart defects (CHDs) in Down syndrome. Using ...
The mice model technologies market offers significant opportunities driven by advancements in genetic engineering, particularly CRISPR/Cas9, fueling drug discovery in oncology, neurobiology, and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback